ra drugs in development stages

MONDAY, DEC. 13, 2010 BIOWORLD® INSIGHT PAGE 19 OF 30
To subscribe, please call BIOWORLD® Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.
Copyright © 2010 AHC Media LLC. Reproduction is strictly prohibited.
American College of Rheumatology
(The 74th annual meeting was held Nov. 7 - 11 in Atlanta.)
Company
(Country)
Product Description Indication Status (Date)#
Alder Biopharmaceuticals
Inc. and
Bristol-Myers
Squibb Co.
ALD518 Anti-IL6 antibody Rheumatoid
arthritis
Phase IIa data showed it reduced disease
activity, induced remission and
improved quality of life (11/9)
Bristol-Myers
Squibb Co.
Orencia Abatacept Rheumatoid
arthritis
Phase III data showed similar improvements
in RA disease activity with its
monthly intravenous drug and a new
formulation given in weekly subcutaneous
injections, following a single
intravenous loading dose (11/9)
ChemoCentryx Inc. CCX354 Oral, small molecule
designed to target
the chemokine
receptor CCR1
Rheumatoid
arthritis
Phase I data showed an excellent safety
profile and that once-daily doses produced
greater than 90% receptor coverage
on blood leukocytes throughout
the day (11/10)
Horizon Pharma
Inc.
HZT-501 A single-tablet formulation
of ibuprofen
and high-dose
famotidine
Pain A long-term safety study showed it
was comparable to ibuprofen alone
and had a two-fold reduction in the
incidence of dyspepsia (11/10)
Horizon Pharma
Inc.
Lodotra A modified-release
formulation of prednisone
Rheumatoid
arthritis
Pivotal data showed a statistically significant
and clinically relevant higher
respone rate evaluated by ACR response
critera in patients treated with 5 mg of
Lodotra compared to placebo, in addition
to standard RA therapy, after 12
weeks of treatment (11/10)
Pfizer Inc. Tasocitinib Oral JAK inhibitor;
CP-690,550
Rheumatoid
arthritis
Phase III data showed that 59.8% (low
dose) and 65.7% (high dose) of
patients achieved ACR20, compared to
26.7% for control (11/9)
Roche AG
(Switzerland)
Actemra Tocilizumab Rheumatoid
arthritis
Phase III data showed that it helped
patients with systemic juvenile idiopathic
arthritis; 85% on drug and 24%
on placebo achieved a 30% improvement
(11/9)
UCB SA (Belgium)
and Immunomedics
Inc.
Epratuzumab A monoclonal antibody
targeting
CD22
Active systemic
lupus erythematosus
Phase IIb data showed that certain
doses were associated with a meaningful
and statistically significant
reduction in disease activity in adult
patients (11/10)
UCB SA (Belgium) Cimzia Certolizumab pegol Rheumatoid
arthritis
Phase IIIb data showed it met its primary
endpoint with 51 . 1% of patients
achieving ACR20 score vs. 25.9% in the
control group (11/10)